Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christina Linton

Nurse Practitioner Provo, UT Nurse Practitioner

NPI 1427074905 CMS profile 10969780

1055 N 500 W, Suite 111, Provo, UT 84604

Open in the dashboard

General payments

$684

43 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christina Linton of Provo, UT is reported in the CMS Open Payments database as having received $684 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $318 17
2024 General $76 4
2023 General $72 4
2022 General $86 6
2021 General $132 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christina Linton
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Christina Linton were reported at $318. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Christina Linton Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $132 $135 $40–$426 $132
2022 $86 $152 $48–$470 $149
2023 $72 $166 $54–$529 $160
2024 $76 $173 $55–$556 $164
2025 $318 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $268 19 payments
  2. Janssen Biotech, Inc. $68 3 payments
  3. Pfizer Inc. $60 4 payments
  4. Novartis Pharmaceuticals Corporation $43 2 payments
  5. Lilly USA, LLC $34 2 payments
  6. Dermavant Sciences, Inc. $33 2 payments
  7. Organon LLC $32 2 payments
  8. Biocon Biologics Inc $31 2 payments
  9. Regeneron Healthcare Solutions, Inc. $29 2 payments
  10. Biofrontera Inc. $23 1 payment
  11. Other $63 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $684 43 payments
Products named General payments · program years 2021–2025
  1. SKYRIZI Immunology $88 9 payments
  2. HUMIRA $78 5 payments
  3. SKYRIZI Immunology $76 4 payments
  4. TREMFYA $68 3 payments
  5. VTAMA $39 3 payments
  6. RINVOQ $36 2 payments
  7. LITFULO $34 2 payments
  8. TALTZ $34 2 payments
  9. Yesintek $31 2 payments
  10. SIMPONI $30 1 payment
  11. Other $335 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

211

Median for Nurse Practitioner: 389

Drug cost

$14,733

Median for Nurse Practitioner: $21,885

Branded share of claims

5.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tazarotene Generic 14 $8,839
Tretinoin Generic 15 $2,076
Clobetasol Propionate Generic 29 $1,478
Triamcinolone Acetonide Generic 68 $731
Finasteride Generic 21 $502
Ketoconazole Generic 27 $442
Doxepin Hcl Generic 14 $322
Ciclopirox Ciclopirox Olamine Brand 11 $206
Mupirocin Generic 12 $136

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$21,674

Medicare's payments for the services billed

Medicare patients

131

Average age 74

Services billed

1,035

79 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 43%
Ischemic heart disease 25%
Depression 25%
Diabetes 24%
Chronic kidney disease 18%
Osteoporosis 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $21
$21 — —
SKYRIZI
  • AbbVie, Inc. $18
$18 — —
LITFULO
  • PFIZER INC. $14
$14 — —
AMELUZ
  • Biofrontera Inc. $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record